Crispr/Cas-based modeling of NF2 loss in meningioma cells

Abstract excerpt

BACKGROUND: Alterations of the neurofibromatosis type 2 gene (NF2) occur in more than fifty percent of sporadic meningiomas. Meningiomas develop frequently in the setting of the hereditary tumor syndrome NF2. Investigation of potential drug-based treatment options has been limited by the lack of appropriate in vitro and in vivo models. NEW METHODS: Using Crispr/Cas gene editing, of the malignant meningioma cell...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Meningioma and schwannoma management
• Share to Nerve injury and regeneration
• Share to Neurofibromatosis and Schwannoma Cases